相似文献
1
Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There?
Cancer J. 2021;27(2):176-181. doi: 10.1097/PPO.0000000000000511.
2
Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Front Immunol. 2020 Aug 7;11:1965. doi: 10.3389/fimmu.2020.01965. eCollection 2020.
3
Allogeneic "Off-the-Shelf" CAR T cells: Challenges and advances.
Best Pract Res Clin Haematol. 2024 Sep;37(3):101566. doi: 10.1016/j.beha.2024.101566. Epub 2024 Jul 25.
4
The paths and challenges of "off-the-shelf" CAR-T cell therapy: An overview of clinical trials.
Biomed Pharmacother. 2023 Dec 31;169:115888. doi: 10.1016/j.biopha.2023.115888. Epub 2023 Nov 17.
5
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Mol Ther. 2019 Jun 5;27(6):1126-1138. doi: 10.1016/j.ymthe.2019.04.001. Epub 2019 Apr 8.
6
Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.
Mol Ther. 2016 Aug;24(7):1178-86. doi: 10.1038/mt.2016.106. Epub 2016 May 16.
7
Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy.
Front Immunol. 2023 Jul 24;14:1199145. doi: 10.3389/fimmu.2023.1199145. eCollection 2023.
8
Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.
Curr Treat Options Oncol. 2022 Feb;23(2):171-187. doi: 10.1007/s11864-021-00920-6. Epub 2022 Feb 25.
9
"Off-the-Shelf" Allogeneic CAR Cell Therapy-Neglected HvG Effect.
Curr Treat Options Oncol. 2023 May;24(5):409-441. doi: 10.1007/s11864-023-01061-8. Epub 2023 Apr 3.
10
Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment.
Curr Pharm Biotechnol. 2024;25(15):2001-2011. doi: 10.2174/0113892010265228231116073012.
引用本文的文献
1
Cell-Based Therapeutic Strategies for Autoimmune Diseases.
Immunotargets Ther. 2025 Apr 28;14:501-514. doi: 10.2147/ITT.S513629. eCollection 2025.
2
Engineering innate immune cells for cancer immunotherapy.
Nat Biotechnol. 2025 Apr;43(4):516-533. doi: 10.1038/s41587-025-02629-5. Epub 2025 Apr 14.
3
γδT cells, a key subset of T cell for cancer immunotherapy.
Front Immunol. 2025 Mar 28;16:1562188. doi: 10.3389/fimmu.2025.1562188. eCollection 2025.
4
From concept to cure: The evolution of CAR-T cell therapy.
Mol Ther. 2025 May 7;33(5):2123-2140. doi: 10.1016/j.ymthe.2025.03.005. Epub 2025 Mar 10.
5
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks.
Nat Rev Clin Oncol. 2025 Jan;22(1):10-27. doi: 10.1038/s41571-024-00959-y. Epub 2024 Nov 15.
6
Allogeneic CAR-T cells for cancer immunotherapy.
Immunotherapy. 2024;16(16-17):1079-1090. doi: 10.1080/1750743X.2024.2408048. Epub 2024 Oct 8.
7
NOT gated T cells that selectively target EGFR and other widely expressed tumor antigens.
iScience. 2024 May 7;27(6):109913. doi: 10.1016/j.isci.2024.109913. eCollection 2024 Jun 21.
8
Advances in Universal CAR-T Cell Therapy.
Front Immunol. 2021 Oct 6;12:744823. doi: 10.3389/fimmu.2021.744823. eCollection 2021.
本文引用的文献
1
Engineering Tolerance toward Allogeneic CAR-T Cells by Regulation of MHC Surface Expression with Human Herpes Virus-8 Proteins.
Mol Ther. 2021 Feb 3;29(2):718-733. doi: 10.1016/j.ymthe.2020.10.019. Epub 2020 Oct 22.
2
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.
Lancet. 2020 Dec 12;396(10266):1885-1894. doi: 10.1016/S0140-6736(20)32334-5.
3
Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
Front Immunol. 2020 Nov 11;11:583716. doi: 10.3389/fimmu.2020.583716. eCollection 2020.
4
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.
Nat Med. 2020 Nov;26(11):1686-1690. doi: 10.1038/s41591-020-1074-2. Epub 2020 Oct 12.
5
Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
Cell Mol Immunol. 2021 Feb;18(2):427-439. doi: 10.1038/s41423-020-0515-7. Epub 2020 Sep 16.
6
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
J Clin Oncol. 2020 Nov 10;38(32):3794-3804. doi: 10.1200/JCO.20.01342. Epub 2020 Jul 23.
7
Engineered off-the-shelf therapeutic T cells resist host immune rejection.
Nat Biotechnol. 2021 Jan;39(1):56-63. doi: 10.1038/s41587-020-0601-5. Epub 2020 Jul 13.
8
Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease.
Blood. 2020 Jul 23;136(4):429-440. doi: 10.1182/blood.2019000953.
9
Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Blood. 2020 Sep 17;136(12):1407-1418. doi: 10.1182/blood.2020005185.
10
Identification of a regulatory Vδ1 gamma delta T cell subpopulation expressing CD73 in human breast cancer.
J Leukoc Biol. 2020 Jun;107(6):1057-1067. doi: 10.1002/JLB.3MA0420-278RR. Epub 2020 May 3.
Zotero 插件